Bionic Sight Overview
- Year Founded
-
2012

- Status
-
Private
- Employees
-
5

- Latest Deal Type
-
Later Stage VC
- Investors
-
4
Bionic Sight General Information
Description
Developer of a medical device designed to develop and commercialize prosthetic treatments for blindness due to retinal degenerative disease. The company's device uses code that can convert visual images into similar patterns of an action potential that the retina normally produces and can do so across a broad range of stimuli including faces, landscapes, and movement, essentially replicating patterns in a code the brain is expecting and can recognize, enabling users to bring prosthetic capabilities up to the level of near-normal image representation.
Contact Information
Website
www.bionicsightllc.comCorporate Office
- 430 East 63rd Street
- Apartment 2-G
- New York, NY 10065-7923
- United States
Corporate Office
- 430 East 63rd Street
- Apartment 2-G
- New York, NY 10065-7923
- United States
Bionic Sight Timeline
Bionic Sight Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Later Stage VC | 01-Feb-2025 | Completed | Clinical Trials - General | |||
4. Later Stage VC (Series A) | 06-Jun-2022 | Completed | Clinical Trials - General | |||
3. Later Stage VC | 01-Mar-2020 | Completed | Clinical Trials - General | |||
2. Later Stage VC | 02-Feb-2017 | $2M | $2M | Completed | Clinical Trials - General | |
1. Early Stage VC | 01-Jan-2014 | Completed | Clinical Trials - General |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Bionic Sight Patents
Bionic Sight Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023307691-A1 | An optogenetic gene therapy for treating blindness | Pending | 09-Jul-2022 | ||
EP-4551243-A1 | An optogenetic gene therapy for treating blindness | Pending | 09-Jul-2022 |
Bionic Sight Signals
Bionic Sight Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Raptor Group | Venture Capital | Minority | ||
Samsara BioCapital | Venture Capital | Minority | ||
Beacon Therapeutics | VC-Backed Company | Minority | ||
Partnership Fund for New York City | Impact Investing | Minority |
Bionic Sight FAQs
-
When was Bionic Sight founded?
Bionic Sight was founded in 2012.
-
Where is Bionic Sight headquartered?
Bionic Sight is headquartered in New York, NY.
-
What is the size of Bionic Sight?
Bionic Sight has 5 total employees.
-
What industry is Bionic Sight in?
Bionic Sight’s primary industry is Therapeutic Devices.
-
Is Bionic Sight a private or public company?
Bionic Sight is a Private company.
-
What is Bionic Sight’s current revenue?
The current revenue for Bionic Sight is
. -
How much funding has Bionic Sight raised over time?
Bionic Sight has raised $10.2M.
-
Who are Bionic Sight’s investors?
Raptor Group, Samsara BioCapital, Beacon Therapeutics, and Partnership Fund for New York City have invested in Bionic Sight.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »